Pasithea Therapeutics (KTTA) Registration filing summary

Company overview and business model

• Clinical-stage biotechnology company focused on CNS disorders, RASopathies, and certain cancers.

• Lead candidate PAS-004 is a next-generation MEK inhibitor targeting MAPK pathway-driven tumors and RASopathies.

• Pipeline includes PAS-003 (ALS) and PAS-001 (schizophrenia), both in early development.

• Discontinued non-core programs and now operates a single therapeutics segment.

Financial performance and metrics

• Net losses of $13.9 million in 2024 and $16.0 million in 2023; accumulated deficit of $49.6 million as of December 31, 2024.

• Cash and cash equivalents of $6.9 million as of December 31, 2024.

• No revenue from operations to date; expects continued losses and need for additional capital.

• Auditor's report includes a going concern warning.

Use of proceeds and capital allocation

• Estimated net proceeds of $4.3 million (assuming full offering), with potential to increase to $13.6 million if all warrants are exercised.

• Proceeds intended for general corporate purposes, including R&D, clinical trials, technology development, licensing, acquisitions, and working capital.

• Management has broad discretion over use of funds.